These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Respigam for protection against RSV. Burke SM MCN Am J Matern Child Nurs; 1996; 21(5):258. PubMed ID: 8840776 [No Abstract] [Full Text] [Related]
4. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection. Handal G; Logvinoff MM; Zegarra N; Allen L; Jesurun A; Levin G; Thida A Tex Med; 2000 May; 96(5):58-61. PubMed ID: 10843015 [TBL] [Abstract][Full Text] [Related]
5. Prevention of respiratory syncytial virus infection in high risk infants. Prince AM; Jacobs RF J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047 [TBL] [Abstract][Full Text] [Related]
6. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627 [TBL] [Abstract][Full Text] [Related]
7. Palivizumab for respiratory syncytial virus prophylaxis. Sandritter T J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084 [TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251 [TBL] [Abstract][Full Text] [Related]
9. Immunoprophylaxis of respiratory syncytial virus infection. Simoes EA Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065 [No Abstract] [Full Text] [Related]
10. Prophylaxis for severe respiratory syncytial virus disease. Kupecz D Nurse Pract; 1996 Sep; 21(9):116-8. PubMed ID: 8884798 [No Abstract] [Full Text] [Related]
14. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Paes B; Steele S; Janes M; Pinelli J Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698 [TBL] [Abstract][Full Text] [Related]